A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Clinical trial NCT06607185 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06607185
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumor Metastatic Solid Tumor

Start date: 2024-10-21
Primary completion: 2030-01-01
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.